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Background: Gestational diabetes mellitus (GDM) is a risk factor for the development of type 2 diabetes. Lifestyle
intervention can prevent progression to type 2 diabetes in high risk populations. We designed a randomised
controlled trial (RCT) to evaluate the effectiveness of an established lifestyle intervention compared to standard care
for delaying diabetes onset in European women with recent GDM. Recruitment into the RCT was more challenging
than anticipated with only 89 of 410 (22%) women agreeing to participate. This paper identifies factors that could
enhance participation of the target population in future interventions.
Methods: We hypothesised that women who agreed to participate would have higher diabetes risk profiles than
those who declined, and secondly that it would be possible to predict participation on the bases of those risk
factors. To test our hypothesis, we identified the subset of women for whom we had comprehensive data on
diabetes risks factors 3-5 years following GDM, reducing the sample to 43 participants and 73 decliners. We considered
established diabetes risk factors: smoking, daily fruit and vegetable intake, participation in exercise, family history of
diabetes, glucose values and BMI scores on post-partum re-screens, use of insulin during pregnancy, and age at
delivery. We also analysed narrative data from 156 decliners to further understand barriers to and facilitators of
participation.
Results: Two factors differentiated participants and decliners: age at delivery (with women older than 34 years being
more likely to participate) and insulin use during pregnancy (with women requiring the use of insulin in pregnancy less
likely to participate). Binary logistic regression confirmed that insulin use negatively affected the odds of participation.
The most significant barriers to participation included the accessibility, affordability and practicality of the intervention.
Conclusions: Women with recent GDM face multiple barriers to lifestyle change. Intervention designers should
consider: (i) the practicalities of participation for this population, (ii) research designs that capitalise on motivational
differences between participants, (iii) alleviating concerns about long-term diabetes management. We hope this work
will support future researchers in developing interventions that are more relevant, effective and successful in recruiting
the desired population.
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The prevalence of gestational diabetes mellitus (GDM) is
growing around the world [1,2], and the adverse mater-
nal and neonatal implications of GDM are now well
established [1,3-7]. GDM is associated with increased
stress and depression during pregnancy [7] and can have
long-term consequences for the mother and child, in-
cluding increased risk of hospital admission, obesity,
heart disease and type 2 diabetes in later life [8-14]. In-
deed, Bellamy et al. [10] found that progression to type
2 diabetes is increased seven-fold in women with prior
GDM compared to women with normal glucose toler-
ance (NGT) in pregnancy.
Since the 1990s, evidence has increasingly demon-
strated that healthy lifestyle intervention and behaviour
modification has the potential to delay if not prevent
progression to type 2 diabetes in high risk populations
[15-21]. For example, the American National Institutes
of Health designed an intensive individualised interven-
tion targeted at improving eating and physical activity
habits, called the Diabetes Prevention Program (DPP).
The DPP led to a 50% reduction in diabetes incidence
in adults with pre-diabetes [18,21]. Similarly the Finnish
Diabetes Prevention Study (FDPS) demonstrated that
weight loss from lifestyle change reduces the incidence of
type 2 diabetes in patients with pre-diabetes [19]. Other
studies have shown lifestyle intervention to be at least as
effective as pharmacological intervention in reducing the
risk of type 2 diabetes in people with impaired glucose
tolerance [22]. Lindstrom et al. [23] found that lifestyle
changes are sustained and the incidence of diabetes re-
duced after the intervention stops.
There is limited evidence, however, to support the effi-
cacy of diabetes prevention programmes in women with a
history of GDM. The most compelling evidence in this
subgroup comes from the DPP which showed a 50% re-
duction in diabetes incidence in women within 10 years of
GDM [24]. Efforts to engage women with a more recent
history of GDM in type 2 diabetes prevention efforts have
largely proven challenging though, due to problems with
uptake of screening services post-pregnancy [25,26] and
recruitment and retention challenges in the case of behav-
iour modification interventions [27,28].
In fact, the literature suggests that women with prior
GDM who are at highest risk of developing type 2 dia-
betes tend to receive the fewest follow-up health care
services [29]. In exploring reasons for non-attendance at
services, a small number of studies have considered risk
perceptions and health behaviours in women with prior
GDM. In terms of risk perception, evidence suggests
that women with prior GDM tend to have an accurate
perception of the general risk of developing type 2 dia-
betes [30,31]. Yet, despite understanding the association
between GDM and future diabetes, women with priorGDM hold inaccurate perceptions of their personal risks
of the disease. Even those women at the highest risk of
developing type 2 diabetes typically do not perceive
themselves to be at an elevated risk as they intend to
modify their health behaviours in the future [30-32].
Notably, studies have shown that having an intention
to engage in health behaviour modification does not al-
ways translate into actual changes in health behaviours.
For example, Kim et al. [30] and Doran and Davis [33]
found that women with prior GDM who perceived them-
selves to be at high risk of developing type 2 diabetes and
planned to modify their future health behaviour were also
associated with the lowest fruit and vegetable consump-
tion, and self-reported no physical activity (or any other
recent modifications to their health or lifestyle behav-
iours). A small number of studies have used qualitative
methodologies to explore the barriers to and facilitators of
post-partum follow-up care in a cohort of women with re-
cent GDM. Bennett et al. [34] found that feelings of emo-
tional stress due to adjusting to a new baby and fear of
receiving a diabetes diagnosis were the primary barriers to
accessing post-partum follow-up care. In fact, women in
their study reported preferring a state of unknowing to
continuing with the necessary behavioural changes, such
as dietary restrictions and blood monitoring, required to
reduce diabetes risks. Fear of receiving bad news has been
reported as a barrier to participation in other intervention
trials too [35].
In an effort to determine the specific factors that could
improve attendance and participation in diabetes pre-
vention programmes, Daspupta et al. [36] invited women
within five years of a GDM diagnosis to a focus group
discussion with the aim of delineating factors that could
enhance participation and engagement in diabetes preven-
tion programmes. Tellingly, of the 1201 women who re-
ceived invitations to participate in the study, only 120
contacted study personnel (10%) and only 29 women ac-
tually attended one of the four focus groups. Discussants
expressed a need for social support to achieve changes in
dietary and physical activity habits. In this regard, face-to-
face interactions with peers and professionals were pre-
ferred, with adjunctive roles for the Internet/social media.
Furthermore, direct participation of partners/spouses
in type 2 diabetes prevention programmes was viewed
as important to enhance support for behavioural change
at home. Discussants highlighted work and child-related
responsibilities as potential barriers to participation, and
emphasised the importance of childcare support to allow
attendance.
Despite this instructive body of work, there is little infor-
mation about the feasibility of offering a lifestyle interven-
tion in a community setting with a population of women
with a recent history of GDM. Further research is required
to understand the characteristics of women who participate
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differ from non-participators in terms of lifestyle, health
status or family history of diabetes. Additionally, we need
a better understanding of the specific difficulties faced by
women with recent GDM in participating in diabetes pre-
vention trials and programmes. Without such under-
standing, we have little evidence to draw from to enhance
participation of this particular group when planning future
RCTs and interventions.
In Ireland, the Atlantic Diabetes in Pregnancy (Atlantic
DIP) programme was established in 2005 to investigate
screening strategies, interventions and follow-up of women
with GDM with a view to diabetes prevention in the long-
term [1]. In routine clinical practice in Ireland there is no
lifestyle modification intervention for women with prior
GDM to reduce the risk of developing type 2 diabetes. In
this context, we designed a randomised controlled trial to
evaluate the feasibility and effectiveness of an established
community-based lifestyle and risk factor modification
intervention, the Croí MyAction programme, compared to
standard health care for delaying diabetes onset in women
with recent GDM [37].
Croí MyAction is a 16 week cardiovascular prevention
programme with an emphasis on lifestyle modification
(smoking cessation, healthy food choices and physical
activity), medical risk factor management (blood pressure,
lipids and glucose) and the prescription of cardio-protective
medication where appropriate. The programme is nurse-
led and delivered by a specially trained multidisciplinary
team (MDT) which includes a dietician, physiotherapist
and physical activity specialist, supported by a physician. The
MyAction model of care evolved from the EuroAction study
[38], which demonstrated that a nurse-managed, multidiscip-
linary, and family-based programme could achieve health-
ier lifestyle changes and better risk factor control than
usual care at one year. Subsequently, Croí MyAction was
established as a partnership between Croí (an Irish heart
and stroke charity) and Imperial College London, the co-
ordinating centre for the EuroAction study [39]. The Croí
MyAction programme has demonstrated striking re-
sults so far in terms of improving adherence to a healthy
diet, reducing both obesity and central obesity and also
significantly improving physical activity levels [40] – all in-
terventions which have been shown to reduce risk of
progression to type 2 diabetes. While Croí MyAction is
designed for individuals at high risk of developing cardio-
vascular disease we anticipate that it will be similarly ef-
fective in reducing long-term diabetes risks in women with
prior GDM.
The RCT is currently underway. However, trial recruit-
ment proved far more difficult than initially anticipated
despite the promise of a free-of-charge lifestyle intervention
for reducing progression from GDM to type 2 diabetes
(Croí MyAction). This paper reports on (i) differencesbetween a subset of participants and decliners in our trial;
and (ii) the reasons for non-participation cited by all de-
cliners. Through this research we hope to foster a better
understanding of barriers to and facilitators of trial partici-
pation for women with prior GDM, and in the process sup-
port the development of interventions that are more
relevant, effective and successful in recruiting the desired
population.
Methods
Our study design, recruitment process and intervention
arms are described elsewhere [37]. Briefly, we invited
410 women with prior GDM to participate in a RCT of
the Croí MyAction lifestyle intervention programme (full
clinical research ethics committee approval was obtained
on 27 March 2012 with an amendment approved on 1
September 2012). Of the total 410 women invited to the
trial, 89 (or 22%) agreed, 156 declined (38%), and the
remainder were not contactable. Among those women
who agreed, 35 did not meet our eligibility criteria of
glucose dysfunction at baseline and were excluded from
the study. Thus a total of 54 women with a history of
GDM and persistent post-partum glucose dysfunction
[impaired glucose tolerance (IGT) or impaired fasting
glucose (IFG)a], have been randomly assigned to a con-
trol arm (n = 27) or to the Croí MyAction intervention
group (n = 27). Women in the control arm receive usual
health care advice, defined as written information on
diet and lifestyle changes for reducing diabetes risks and
visits with general practitioners as required. The interven-
tion group receives usual health care as per the control
group in addition to attending the 12-week Croí MyAction
lifestyle modification programme. Croí MyAction com-
prises a group exercise programme, group health promo-
tion or education seminars, and one-to-one meetings with
a multidisciplinary health care team focusing on persona-
lised risk factor reductions.
For this paper, we wanted to examine the characteris-
tics of the participants versus the decliners to isolate any
key differences that might be predictive of participation.
Upon analysis of the available dataset, we identified 43
out of the 89 participants and 73 out of 156 decliners who
had returned for follow-up testing 3-5 years post-partum
[41]. The statistical analyses in this paper draw from the
clinical, anthropometric and demographic characteristics
of this sample of 116 women. In addition, we summarise
barriers to participation in the trial from the total number
of decliners (n = 156). All of these women are part of an
ongoing research study on gestational diabetes known as
Atlantic Diabetes in Pregnancy (DIP) programme, which
has been running since 2005. Each woman has given
her consent in writing for her personal health data to be
used as part of the ongoing research programme. The
women are free to decline to participate in any particular




n = 43 (37%)
Declined to
participate








No 22 (35%) 41 (65%) 63 0.601
Yes 21 (40%) 32 (60%) 53
Smoker
Past 17 (41%) 25 (59%) 42 0.790
Current 7 (39%) 11 (61%) 18




No 5 (31%) 11 (69%) 16 0.604




No 0 3(100%) 3 0.178
Yes 43 (38%) 70 (62%) 113
Insulin use during
pregnancy
No 33 (46%) 38 (54%) 71 0.008
95% CI
(7.5, 41)
Yes 10 (22%) 35 (77%) 45
IFG at follow-up
No 34 (36%) 61 (64%) 95 0.544
Yes 12 (57%) 9 (43%) 21
IGT at follow-up
No 41 (38%) 68 (62%) 109 0.631
Yes 2 (29%) 5 (71%) 7
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the Clinical Research Ethics Committee of Galway University
Hospital for the conversion study [41] in March 2011, and
for the clinical trial in 2012.
We hypothesised that there would be differences be-
tween participants and decliners to the trial based on
known type 2 diabetes risk factors, and that we would be
able to predict probability of participation based on
these risk factors. Therefore, the primary response vari-
able of interest is whether a person agreed to participate
in the intervention or not. The explanatory variables in-
clude the following known type 2 diabetes risk factors: first
degree relative with diabetes mellitus (DM); smoking sta-
tus; exercise participation; daily fruit and vegetable intake;
insulin use during pregnancy; post-pregnancy impaired
fasting glucose (IFG); post-pregnancy impaired glucose tol-
erance (IGT); fasting plasma glucose (FPG) value and 2-
hour plasma glucose (PG) value, 3-5 years following GDM;
body mass index (BMI); and the covariate, age at delivery.
To test our hypotheses, two different approaches were
used. First, in order to describe the variables in question
and to identify any differences between participants and
decliners on those variables, we undertook univariate
analysis using Chi-square and T-tests. The Chi-square
analysis investigated associations between participants
and decliners based on the following categorical vari-
ables: family history of type 2 diabetes (yes/no), current
smoking status (yes/no), meets daily exercise intake re-
quirements (yes/no), meets daily fruit and vegetable in-
take requirements (yes/no), insulin use during GDM
pregnancy (yes/no), and whether blood glucose values met
the diagnostic criteria for either or both of IFG or IGT on a
post-partum oral glucose tolerance test (OGTT) (yes/no).
T-tests were used to compare the participants and decliners
across the continuous variables of: FPG values, 2-hour PG
values, BMI and age at delivery.
Secondly, in order to identify variables that may be
useful predictors of participation we undertook multi-
variate analysis, in the form of: logistic regression ana-
lysis (using variable selection procedures and the least
absolute shrinkage and selection operator [LASSO]; and
classification tree analysis (pruned on misclassification).
All statistical analyses were carried out with Minitab
(version 16) and R (version 2.15) software, using rpart,
rpart.plot and beanplot libraries. Model checking was
based on deviance and the Hosmer-Lemeshow test. Fi-
nally, we summarised the stated barriers to participation
available from the 156 decliners.
Results
Comparison of participants to decliners
Chi-square analysis and T-tests
The Chi-square test of independence was performed to
determine if participants and decliners are distributeddifferently depending on their health status, using Fisher’s
exact test when appropriate. The results of this analysis
are presented in Table 1. Only one significant association
was found: women that used insulin during the index
GDM pregnancy were associated with lower participation
rates than those that did not use insulin in pregnancy: χ2
(1, N = 116) = 6.947, p < .01. Of the total number of
women who used insulin, only 22% agreed to participate
in the trial (77% declined); whereas 46% of those who did
not use insulin agreed to participate (54% declined).
T-tests of differences between the 43 participants and
73 decliners are presented in Table 2. There was no evi-
dence against normality for the continuous variables. The
groups differed significantly on one variable: age at deliv-
ery. On average, participants were 2 years older.
Table 2 T-tests of differences between participants and decliners
Continuous variables
Consented to
participate (n = 43)
Declined to
participate (n = 73)
95% Confidence interval (CI),
Consent-No consent
P-value
Mean (SD) Mean (SD)
Fasting plasma glucose at follow-up 5.3 (0.63) 5.2 (0.71) (-0.34, 0.17) 0.526
2-hour plasma glucose at follow-up 5.4 (1.55) 6.3 (2.37) (-0.06, 0.11) 0.619
BMI at follow-up 33.3 (5.98) 32.1 (6.59) (-3.52, 1.24) 0.344
Age at delivery 36.1 (4.48) 34.1 (5.05) (0.21, 3.8) 0.029
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36 years while the mean age at delivery for decliners was
34 years. There was no evidence against normality for the
continuous variables in question.
Predicting probability of participation
Binary logistic regression analysis
Logistic regression analysis using variable selection and the
LASSO was used to identify useful predictors of participa-
tion in the trial. The analysis identified insulin use during
pregnancy and age at delivery as the only significant pre-
dictors of the probability of participation. The ‘meets daily
fruit and vegetable intake’ variable was not included in the
logistic regression analysis due to small cell counts.
Table 3 shows the model estimates from both the full
and reduced models. The reduced model identified two
useful predictors; namely, age at delivery, and whether
an individual was on insulin or not during pregnancy.
From the table it can be seen that the estimated oddsTable 3 Full and reduced binary linear regression models of c
Full model*
Variable OR Lower Upper
Age (years) 1.12 1.01 1.23
First degree relative
(Yes vs. No) 0.77 0.32 1.85
Smoker
(Past vs. Never) 1.91 0.72 5.06
(Current vs. Never) 1.65 0.46 5.93
Exercise
(Yes vs. No) 0.98 0.27 3.49
Insulin use
(Yes vs. No) 0.35 0.14 0.86
IFG at follow-up
(Yes vs. No) 1.27 0.43 3.77
IGT at follow-up
(Yes vs. No) 0.59 0.09 3.94
BMI 1.04 0.97 1.11
C statistic: Full = 0.71, Reduced = 0.68.
*Fruit and vegetable intake excluded due to sparse data (113/116 had adequate fruof participating increase by 1.12 per unit increase in
age; and are 0.35 times lower for insulin users com-
pared to non-insulin users. The odds ratio, however,
gives no indication of the underlying probability of an
individual participating in the trial. Rather, it provides
the multiplicative effect on the odds based on a refer-
ence category (for a categorical predictor) or per unit
increase (for a continuous predictor). Thus, a plot of the
corresponding estimated probability is needed to highlight
the effect of increasing age for insulin and non-insulin
users (Figure 1).
Classification tree analysis
A classification tree (pruned on misclassification) was
grown to identify useful cutpoints for the potential predic-
tors of participation (Figure 2). The (pruned) classification
tree identified insulin use and age at delivery as useful pre-
dictors; that is, those women using insulin during the index
pregnancy, irrespective of age, were classified as decliners;onsent to participate
Reduced model (LASSO)
P-value OR Lower Upper P-value







































Age at Delivery:  1.09     (1.00, 1.18)
Insulin Use:        0.34     (0.15, 0.80)
                          OR          95% CI 
Figure 1 Scatter plot of predicted probability of participation.
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fied as participators; and women not using insulin and ≤ 34
years were classified as decliners.
The predictive ability of the tree is assessed by looking
at the proportion of women correctly classified by the
tree. Figure 2 shows the number of women correctly
classified and the corresponding percent correctly classi-
fied at each (terminal) node. For example, if insulin use
alone was used as a classifier for non-participation, 78%
(of those taking insulin) were correctly classified. Those
not using insulin during pregnancy and > 34 years were
classified as participants, with a correct classification rate
of 57%. Those that did not use insulin during pregnancy
and ≤ 34 years were classified as decliners, with a correct
classification rate of 69%. Overall, 79 of the 116 women
(68%) were classified correctly by the tree model.
Comparison summary
In summary, there were no significant differences be-
tween participants and decliners on lifestyle variables
(smoking behaviour, healthy eating behaviour and exer-
cise behaviour) or in terms of their diabetes status (IFG,
IGT, FPG, 2-hour PG), BMI, or family history of diabetes.Insulin use
Declined to participate Declined to par
Used insulin (n=45)
35/45 = 78% correctly classified 20/29 = 69% correc
≤34 years
Figure 2 Classification tree for participation.Participants and decliners differed significantly on two
variables: age at delivery (with women older than 34 years
being more likely to participate) and insulin use for glu-
cose control during pregnancy (with women requiring the
use of insulin less likely to participate). In terms of pre-
dicting participation, the evidence suggests that, for this
sample, the factors significantly predictive of probability of
participation are age at delivery and insulin use during
pregnancy. However, the model gives no indication as to
which split in age is most informative. The classification
tree suggests that the effect of age is most informative
when considering individuals above and below 34 years of
age. It should be noted, however, that neither the logistic
model nor the tree are intended to be used as prediction
algorithms. Rather, they help to identify potentially useful
predictors and potentially useful cutpoints for continuous
predictors. The cutpoint identified here supports the exist-
ing evidence that older women are more likely to partici-
pate in research than younger women [31].
Barriers to participation cited by decliners
Stated barriers to participation in the trial are available
from the 156 decliners and are described in Table 4. Inticipate Consented to participate
Age
Did not use insulin (n=71)
tly classified 24/42 = 57% correctly classified
 (n=29) >34 years (n=42)
Table 4 Barriers to participation cited by decliners
Barrier category Description Number of times cited
(and percentage of
respondents who cited barrier)
Travel distance/Transport Distance to location of intervention; travel expense; lack of transportation 80 (51%)
Child care commitments Cannot leave children; do not want to leave children; children too young
to leave; lack of childcare; leisure time dedicated to children/family activities
52 (33%)
Lack of time/Too busy Lack of time to commit to the programme; time commitment required too great;
unable to commit to specific times; own and partners’ work schedules; child’s




Research fatigue; discomfort with test procedures; programme times/content 26 (17%)
Not concerned about diabetes
risks
Given the all clear on post-partum tests, therefore not concerned about risks 23 (15%)
Lack of social support Lack of a network of friends or family to provide practical or emotional support 9 (6%)
Already taking action on own Does not need this programme as taking action on her own 8 (3%)
Health too poor to participate Acute health problems take precedence over chronic health problems 3 (2%)
Other reasons Planning a pregnancy; caring for parents; learning English; currently living abroad 6 (4%)
No reason given Not interested in participating 4 (3%)
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women cited several reasons for declining to take part in
the intervention. Coded statements were grouped into
themes that reflected similar or related barriers.
Above all, travel distance, child care commitments and
lack of time to devote to the programme presented the
most significant barriers to participation for this cohort
of women. This finding is not surprising given the target
population: women with recent GDM, many of whom
have other children and also work outside the home. In-
deed, such barriers have been shown to be particularly
relevant to women [34,35]. Many of the women invited
to our trial were from rural areas up to a 2-hour drive
from the intervention site. For these women, the travel
distance and expense, in addition to the length of the
programme, was a prohibitive factor. A number of women
simply stated that they had children at home and therefore
could not attend the programme, some qualifying this
statement by saying that they did not want to leave the
children but would prefer to spend any spare time they
had with their children; others said their children were too
young to leave. Many specified that, with the demands of
their own schedules and their partners’ schedules, they
could not commit to being able to leave the family at a
regularly scheduled time each week.
Research fatigue also emerged as a significant reason for
non-participation for the population of women targeted in
this study. This finding may reflect the fact that an inten-
sive programme of research on the issue of GDM has been
ongoing in the region for over five years, and the women
invited to participate in this trial had all been involved in
earlier phases of the research. Moreover, one of the base-
line tests - the Oral Glucose Tolerance Test - requiresfasting for a minimum of 8 hours prior to the test, then 3
blood draws over the course of 2 hours. This procedure in
itself presented a barrier to participation for some women.
On the other hand, a significant number of women were
not concerned about their health or diabetes risks and felt
they were not in need of the intervention programme as
they intended to take action to improve their health. This
finding affirms those of other studies on women with
GDM [30]. Finally, although lack of social support was
only explicitly identified by a small number of women as a
reason for declining to take part in the trial, it appeared
to be an important confounding factor in many of the
other barrier categories too. Essentially, if there was no
one else to assume the responsibilities of running the
home and caring for children, it felt prohibitively difficult
for many women to commit to a time-intensive interven-
tion programme requiring a regular commitment of time.
Discussion/conclusions
Of a fairly large potential candidate population, relatively
few women who received information about the trial agreed
to participate. For the following reasons we expected up-
take to be higher:
 The intervention (Croí MyAction programme) is
delivered in an accessible, non-medical community
setting, free-of-charge to participants;
 The intervention offers flexible options for delivery (for
example, a home-based option with fewer on-site visits
is available, if necessary) and allows participants to
make up missed sessions on future programme dates;
 The intervention combines individual and group-based
components, and encourages participants to enrol a
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support and motivation outside programme times;
 The program is multidisciplinary, recognising that
changing lifestyle and health behaviour requires the
expertise of a variety of health care professionals;
 The intervention has very high uptake, retention
and success rates with its current target population
(individuals at high risk of cardiovascular disease).
Additionally, since the initiation of the Atlantic DIP re-
search programme in 2005, health care providers in our
region have increased their focus on providing accessible
and relevant clinical recommendations to women with
GDM during all antenatal visits. Thus it was expected that
women would be motivated to improve their health fol-
lowing GDM.
Overall, the results do not support our hypothesis that
participants and decliners differ significantly in their dia-
betes risk profiles. In fact, in this population, the groups
did not differ significantly on lifestyle variables (smoking
behaviour, healthy eating behaviour and exercise behav-
iour), diabetes status (IFG, IGT, FPG, 2-hour PG), BMI,
or family history of diabetes. Participants and decliners
differed significantly on only two variables: age at delivery
(with women older than 34 years being more likely to par-
ticipate) and insulin use during pregnancy (with women
requiring the use of insulin less likely to participate).
Our finding on age is consistent with other studies
(for example, see [31]) which suggest that older women
tend to participate in prevention studies more frequently
than younger women. The finding on insulin use, how-
ever, was contrary to our expectations and previous re-
search [30,31]. We hypothesised that women requiring
insulin during their GDM pregnancy would be more
cognisant of the severity of diabetes and their personal
risks of developing type 2 diabetes and therefore more
motivated to avoid the disease. However, the opposite
was found in this sample. Interestingly, Bennett et al.
[34] found that women who were at highest risk of de-
veloping diabetes, based on antenatal glucose testing and
requirement of insulin during pregnancy, appeared to re-
ceive the fewest post-partum follow-up care services.
Bennett’s study concluded that women’s concerns about
their post-partum and future health actually prevented
them from accessing follow-up medical care and moni-
toring. At this point in our study, we are uncertain if
similar anxieties associated with receiving a diabetes
diagnosis may have been a deterrent to participation.
We are conducting interviews with participants in our
trial upon completion of the intervention to explore
their pre- and post-programme health concerns. If time
permits, we also intend to invite a subset of the decliners
for telephone interviews to further explore their reasons
for non-participation.The uptake rate for our study was low: of the 410
women invited to participate in the trial, only 89 (22%)
agreed. As summarised in Table 4, many of the women
invited to participate in the trial simply did not consider
the intervention accessible, affordable or practical given
their lifestyle and carer responsibilities. To put this in
context, the average uptake rate for the Croí MyAction
(cardiac care) programme is 93%, and the adherence rate
(87%) and 1 year retention rate (94%) are also extremely
high [40]. However, these patients are mostly older than
our population, and include both males and females. The
referral method is also different, with attendees typically
being referred to Croí MyAction by their physicians.
Evidence suggests that uptake and adherence rates
are generally lower in primary than secondary preven-
tion interventions, likely because individuals attending
the former have not experienced a life threatening event.
The Diabetes Prevention Program (DPP) and the Finnish
Diabetes Prevention Study, for example, reported rela-
tively low levels of participation with community-based
diabetes prevention interventions [42] [21]. Similar prob-
lems with recruitment and retention have been reported
in the cardiac rehabilitation literature too [43] [44], where
uptake rates are an average of 44% and drop-out rates
range from 30% to 50%. The barriers to participation re-
ported in the above literature are similar to those identi-
fied in our study, and include: service-related factors (for
example, limited programme capacity or timings of ses-
sions); patient-related factors (e.g. distance to travel, being
older, being female, and having comorbidities) [45,46];
psychological barriers such as depression, anxiety and lack
of social support [47]; and beliefs about health self-efficacy
[48]. Other studies on participation in research have simi-
larly cited childcare and work conflicts as posing barriers
[49,50], such barriers are likely to be particularly relevant
to women [35].
Overall, the evidence suggests that uptake of lifestyle
modification programmes is challenging for any segment
of the population but particularly so for women with
children. The method of recruitment into the programme
also seems important, with physician-led recruitment
likely to be more effective than mail-outs or advertising
methods. However, the most effective methods for recruit-
ing potential participants vary according to the gender,
age, and race/ethnicity of those individuals and ongoing
assessment and revision of the recruitment strategy is
therefore valuable [51].
Lessons learned
Women with recent GDM face multiple barriers to life-
style change. “For them, illness and its management can-
not be separated from the broader circumstances of
their lives, and many factors compete for the time and
attention that treatment regimens require” [52] (p.361).
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Like other behavioural interventions, the recruitment
process into the trial was relatively demanding in terms
of researcher time and resources and the recruitment
rate was lower than anticipated. While the trial is not
yet complete, a number of lessons to increase recruit-
ment into similar future interventions are already appar-
ent. We share these below with the objective of assisting
other researchers planning RCTs and diabetes preven-
tion programmes which are targeting the same demo-
graphic of women with recent GDM.
Feasibility studies
Health behaviours are clearly influenced by complex and
contextual social, economic and cultural factors, values,
beliefs and constraints [53]. As such, to maximise par-
ticipation in a study aimed at lifestyle modification and
behaviour change, the design and implementation of the
intervention needs to give serious consideration to the
practicalities of the everyday lives of the target partici-
pants. Preliminary research (for example, qualitative stud-
ies, feasibility studies or pilot trials) should be undertaken
to identify these practical details and determine whether
the trial is feasible for the target population.
Address logistical barriers to participation
Historically, women have been under-represented in clin-
ical trials for various reasons [54-57]. As ours and other
studies have shown, the non-participation of women is
strongly influenced by logistical issues related to childcare,
work responsibilities, travel time and expense, amongst
others [34,35,49,50,55]. Given these barriers, to maximise
the recruitment of this demographic into RCTs and life-
style interventions, issues of convenience, relevance and
carer-responsibilities must be addressed. This includes, for
example, offering home-based study assessments; provid-
ing on-site child care facilities; ensuring a wide variety of
times and modalities for the intervention; and offering the
intervention locally. In general, Hunt et al. [52] instruct
that “future intervention[s] need to go further in balancing
clinical efficacy with the various and competing nonmedi-
cal factors that women with GDM confront on a daily
basis, such as the demands of employment, family and
economic obligations” (p.362).
Appropriate trial design
Lifestyle intervention trials differ from traditional treat-
ment trials as participants in the former are at risk of a
condition rather than living with a diagnosed condition
[58]. Lifestyle intervention designed to prevent a disease
or condition requires the considerable time, commit-
ment and motivation of participants. Moreover, patients
often have strong preferences for one treatment overanother. For these reasons, Brewin and Bradley [59]
argue that such trials should be conducted differently
from treatment trials. Their argument is compelling; in
essence, if the effectiveness of a lifestyle or behavioural
intervention is evaluated after random administration of
patients (who may or may not desire the treatment) it
will be difficult to distinguish between a treatment that
failed because it was not inherently effective and one
that failed because it was not targeted towards patients
who were suitably motivated. “Problems of interpretation
are bound to arise when trials of participative treatments
are designed as though they are drug trials without con-
sidering the different psychological processes concerned
in each” [59] (p.315). Thus, random allocation – which is
considered a great strength in traditional RCTs – can be
considered a weakness in lifestyle/behavioural inter-
vention trials because it eliminates participant choice.
Choosing one’s preferred intervention, it is argued, can in-
crease motivation and thereby the success of the interven-
tion [53,60]. One solution here may be to adopt a
non-randomised approach which capitalises on, rather
than ignores, motivational differences between partici-
pants by allowing patient choice to dictate the interven-
tion group rather than chance allocation. Such studies
have the potential to tell us whether treatment interven-
tions are viable options for patients who choose to use
them.
Alternatively, rather than abandoning the RCT com-
pletely, realistic compromises should be considered dur-
ing the design stage in order to increase the potential
attractiveness of a trial to participants. For example,
patient-preference RCTs – while not without their own
limitations – are widely used [61], or simply ensuring
that the control arm of an intervention trial is an attract-
ive option for participants while maintaining investigator
equipoise about which intervention is most effective.
Risk perception and behaviour change
As ours and other studies suggest (see [30,33]), aware-
ness of GDM as a risk factor for type 2 diabetes may not
be sufficient to increase personal risk perception and
motivate women to change their lifestyle and health be-
haviours. Other factors such as emotional stress and fear
of diagnosis have been shown to present significant bar-
riers to participation in follow-up health care programmes.
There is evidence too that women with GDM have higher
levels of perceived pregnancy “hassles” and higher rates of
clinical depression [7]. The extent to which this persists
after childbirth and between pregnancies is not known,
but it is likely that worry about subsequent pregnancies
is present for many women who had GDM. To address
this, health care providers and researchers must ensure
they are providing sufficiently reassuring information
about how GDM can be successfully managed in order to
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participants.
Finally, it seems instructive to note that while individual
risk perception does not always result in actual behaviour
change, it may still indicate a readiness to change [31]. In
this respect, researchers should consider integrating cog-
nitive behavioural strategies into lifestyle interventions not
only to address the underlying psychological barriers that
mitigate success in regard to behaviour change, but also to
assist women who are still ‘pre-contemplators’ in regard
to lifestyle modification to progress towards the stages of
contemplation and taking action [62].
In the end, lifestyle intervention in people at high risk
for type 2 diabetes can result in sustained changes and a
corresponding reduction in the burden of the disease
well after the intervention stops [23]. As such, it is im-
perative to understand the motivators and barriers to
participation in such interventions for women with prior
GDM. Our study team has learned a number of practical
lessons from recruitment into the current trial. We plan
to incorporate these lessons – along with the analysis of
trial outcomes – into the design of a larger trial of a re-
vised intervention, anchored in evidence of what works
best for this cohort of women in the Irish context.
Endnotes
aThe glucose levels used to diagnose IFG and IGT in
this study are based on the 2010 recommendations of
the American Diabetes Association. GDM was diagnosed
based on the recommendations of the International
Association of Diabetes and Pregnancy Study Groups
(IADPSG) [63].
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